Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 670-675

  McDermott, Shaunagh ^a   Thayer, Sarah P ^a   Castillo, Carlos Fernandez Del ^a   Mino Kenudson, Mari ^a   Weissleder, Ralph ^a   Harisinghani, Mukesh G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERUMOXYTOL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PILOT STUDY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

EID: 84891704327     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13400     Document Type: Article

References (37)

1. Siegel R, Naishadham D, and Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin 63 (1), 11-30.
2. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, and Hruban RH (2012). Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res 18 (16), 4257-4265.
3. Yachida S (2012). Novel therapeutic approaches in pancreatic cancer based on genomic alterations. Curr Pharm Des 18 (17), 2452-2463.
4. Cinar P and Tempero MA (2012). Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J 18 (6), 653-664.
5. Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, et al. (2012). Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 82 (4), e595-e601.
6. Petit SF, Wu B, Kazhdan M, Dekker A, Simari P, Kumar R, Taylor R, Herman JM, and McNutt T (2012). Increased organ sparing using shape-based treatment plan optimization for intensity modulated radiation therapy of pancreatic adenocarcinoma. Radiother Oncol 102 (1), 38-44.
7. Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, and Springett G (2011). Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 104 (2), 155-161.
8. Ren F, Xu YC, Wang HX, Tang L, and Ma Y (2012). Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? Pancreatology 12 (2), 162-169.
9. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, et al. (2012). A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderlineresectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12, 199.
10. Kircher MF, Hricak H, and Larson SM (2012). Molecular imaging for personalized cancer care. Mol Oncol 6 (2), 182-195.
11. Wehr AY, Furth EE, Sangar V, Blair IA, and Yu KH (2011). Analysis of the human pancreatic stellate cell secreted proteome. Pancreas 40 (4), 557-566.
12. Mahadevan D and Von Hoff DD (2007). Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6 (4), 1186-1197.
13. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, et al. (2011). Stromal biology and therapy in pancreatic cancer. Gut 60 (6), 861-868.
14. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, et al. (2009). A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6 (4), e1000046.
15. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, and Weissleder R (2003). Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (25), 2491-2499.
16. Tatsumi Y, Tanigawa N, Nishimura H, Nomura E, Mabuchi H, Matsuki M, and Narabayashi I (2006). Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer 9 (2), 120-128.
17. Memarsadeghi M, Riedl CC, Kaneider A, Galid A, Rudas M, Matzek W, and Helbich TH (2006). Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology 241 (2), 367-377.
18. Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, Oram DH, Jacobs IJ, Shepherd JH, and Reznek RH (2005). Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 23 (12), 2813-2821.
19. Hasan D, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, Young WL, Hashimoto T, Winn HR, and Heistad D (2012). Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke 43 (12), 3258-3265.
20. Hasan DM, Chalouhi N, Jabbour P, Magnotta VA, Kung DK, and Young WL (2013). Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. J Neuroradiol 40 (3), 187-191.
21. Harisinghani M, Ross RW, Guimaraes AR, and Weissleder R (2007). Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 9 (12), 1160-1165.
22. Saksena M, Harisinghani M, Hahn P, Kim J, Saokar A, King B, and Weissleder R (2006). Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. AJR Am J Roentgenol 187 (6), W582-W588.
23. Torabi M, Aquino SL, and Harisinghani MG (2004). Current concepts in lymph node imaging. J Nucl Med 45 (9), 1509-1518.
24. Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kikka I, Alanen K, Borra RJ, Puolakkainen PA, et al. (2009). A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250 (6), 957-963.
25. Imai H, Doi R, Kanazawa H, Kamo N, Koizumi M, Masui T, Iwanaga Y, Kawaguchi Y, Takada Y, Isoda H, et al. (2010). Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer. Int J Clin Oncol 15 (3), 294-300.
26. Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T, and Iguchi H (2013). Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas 42 (1), 11-19.
27. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakashima A, Yuasa Y, Kondo N, Ohge H, and Sueda T (2010). Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 211 (2), 196-204.
28. Schwarz RE and Smith DD (2006). Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 13 (9), 1189-1200.
29. Riediger H, Keck T, Wellner U, Zur Hausen A, Adam U, Hopt UT, and Makowiec F (2009). The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13 (7), 1337-1344.
30. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, and Pawlik TM (2008). Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15 (1), 165-174.
31. House MG, Gönen M, Jarnagin WR, D'Angelica M, DeMatteo RP, Fong Y, Brennan MF, and Allen PJ (2007). Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 11 (11), 1549-1555.
32. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, et al. (2007). Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141 (5), 610-618.
33. Massucco P, Ribero D, Sgotto E, Mellano A, Muratore A, and Capussotti L (2009). Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers. Ann Surg Oncol 16 (12), 3323-3332.
34. Doi R, Kami K, Ito D, Fujimoto K, Kawaguchi Y, Wada M, Kogire M, Hosotani R, Imamura M, and Uemoto S (2007). Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg 31 (1), 147-154.
35. Lafemina J, Chou JF, Gönen M, Rocha FG, Correa-Gallego C, Kingham TP, Fong Y, D'Angelica MI, Jarnagin WR, Dematteo RP, et al. (2013). Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? J Gastrointest Surg 17, 1092-1097.
36. Maithel SK, Khalili K, Dixon E, Guindi M, Callery MP, Cattral MS, Taylor BR, Gallinger S, Greig PD, Grant DR, et al. (2007). Impact of regional lymph node evaluation in staging patients with periampullary tumors. Ann Surg Oncol 14 (1), 202-210.
37. Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Fernández-del Castillo C, Warshaw AL, and Thayer SP (2013). N0/ N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 17 (2), 257-266.